Brian McCaughan
Overview
Explore the profile of Brian McCaughan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hyland R, Chrzanowska A, Hannaford-Turner K, Davis A, Ke H, Bradbury L, et al.
Asia Pac J Clin Oncol
. 2022 Jan;
18(5):e448-e455.
PMID: 35100476
Background And Objectives: Due to difficulties in identifying sufficient-sized cohorts there remains uncertainty about prognostic and clinical differences that may be unique to asbestos-related lung cancer (ARLC). In this study,...
2.
Hulme K, Mahar A, Cao C, McCaughan B, Cooper W
Pathology
. 2021 May;
53(7):930-933.
PMID: 33947520
No abstract available.
3.
Williams M, Cheng Y, Kirschner M, Sarun K, Schelch K, Winata P, et al.
Oncotarget
. 2019 Jul;
10(41):4125-4138.
PMID: 31289611
MicroRNA downregulation is frequent in malignant pleural mesothelioma (MPM), but the mechanisms responsible for loss of miR-15/16 and miR-193a are yet to be elucidated and were investigated in this study....
4.
Ahmadzada T, Lee K, Clarke C, Cooper W, Linton A, McCaughan B, et al.
Lung Cancer
. 2019 Mar;
130:35-41.
PMID: 30885349
Objectives: A number of key immune regulators show prognostic value in malignant pleural mesothelioma (MPM), but the association between Bridging integrator 1 (BIN1), indoleamine 2,3 dioxygenase 1 (IDO1) and patient...
5.
Harris E, Kao S, McCaughan B, Nakano T, Kondo N, Hyland R, et al.
J Thorac Oncol
. 2018 Oct;
14(2):288-293.
PMID: 30366103
Introduction: Malignant pleural mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centers to highly selected patients. A...
6.
Lau B, Kumar S, Yan T, Burn J, Kennedy C, McLean J, et al.
Lung Cancer
. 2017 Aug;
111:75-78.
PMID: 28838403
A small proportion of patients with malignant pleural mesothelioma (MPM) achieve pathological complete response (CR) following treatment with current practice induction chemotherapy. Our analysis of 58 patients with MPM treated...
7.
Kao S, Cheng Y, Williams M, Kirschner M, Madore J, Lum T, et al.
J Thorac Oncol
. 2017 Jun;
12(9):1421-1433.
PMID: 28629895
Introduction: The upregulation of programmed death ligand 1 (PD-L1) is found in many cancers and contributes to evasion of the host's immune defense. In malignant pleural mesothelioma (MPM), PD-L1 expression...
8.
Iedema R, Verma R, Wutzke S, Lyons N, McCaughan B
J Health Organ Manag
. 2017 May;
31(2):223-236.
PMID: 28482771
Purpose To further our insight into the role of networks in health system reform, the purpose of this paper is to investigate how one agency, the NSW Agency for Clinical...
9.
Lemech C, Williams R, Thompson S, McCaughan B, Chin M
BMC Res Notes
. 2016 Aug;
9:386.
PMID: 27488020
Background: Follicular dendritic cell sarcoma is a rare tumour with clinical behaviour covering a spectrum from indolent to aggressive disease. Treatment recommendations are currently based on case reports and small...
10.
Kao S, Kirschner M, Cooper W, Tran T, Burgers S, Wright C, et al.
Br J Cancer
. 2016 Feb;
114(5):524-31.
PMID: 26889976
Background: We aimed to identify prognostic blood biomarkers using proteomics-based approaches in malignant pleural mesothelioma (MPM). Methods: Plasma samples from 12 MPM patients were used for exploratory mass spectrometry and...